#USA #Milford #Waters Corporation #BioResolve #Protein A

Waters Corporation Launches BioResolve Protein A Affinity Columns

Introduction

On May 28, 2025, Waters Corporation, trading under NYSE: WAT, made a groundbreaking announcement with the launch of their new BioResolve™ Protein A Affinity Columns equipped with MaxPeak™ Premier Technology. This innovation marks Waters' entry into the realm of affinity chromatography columns designed to transform the way antibody titer measurements are conducted.

Key Features of BioResolve Protein A Affinity Columns

The BioResolve Protein A Affinity Columns are engineered to elevate the efficiency of measuring antibody titers, offering advantages that could significantly impact biopharmaceutical development. Here are some of the key features:

1. Accelerated Measurement: These columns enable measurements to be conducted up to two days earlier, facilitating selections during the clone selection process and bioprocess monitoring.
2. Enhanced Sensitivity: The columns provide an outstanding improvement in sensitivity—up to seven times greater than existing market leaders. This is crucial for detecting low concentrations of antibodies, allowing for efficient titer measurements based on standard Chinese Hamster Ovary (CHO) cell line doubling times.
3. Streamlined Workflows: The use of non-porous 3.5 μm particles allows for accurate assessments of titer concentrations and aggregate analysis in a single analytical run, thus simplifying laboratory processes.

Comments from Leadership

Dr. Udit Batra, the President and CEO of Waters Corporation, expressed that this innovative product is fundamentally designed to expedite the delivery of lifesaving therapies to patients. The bottleneck often faced during the development phase of biotherapeutics, especially monoclonal antibodies, is primarily the duration taken to pinpoint and refine an appropriate cell line for production. Dr. Batra emphasized the significance of this product, asserting, “We have solved for this by designing a novel, highly efficient particle with an immobilized Protein A surface.”

Application and Benefits

The BioResolve Protein A Affinity Columns have been crafted to work seamlessly with size exclusion chromatography columns, enabling simultaneous analyses in a single run across various liquid chromatography (LC) systems. Arnaud Delobel, RD and Innovation Director at Quality Assistance, highlighted that this dual analysis capability cuts down project turnaround times and supports faster market entry for biologics.

• - Faster Development: The innovations brought by these columns are anticipated to enhance the effectiveness and speed of new medicine development significantly.
• - Integration with Existing Systems: Coupled with advanced LC/MS setups, these columns can analyze in-process antibody samples without necessitating prior purification, further optimizing workflow.
• - Quality Assurance: These capabilities facilitate the simultaneous evaluation of multiple critical quality attributes (CQAs), thereby fitting into a modernized framework for quality control in biopharmaceutical laboratories, aligning with the strict exigencies of today's healthcare landscape.

Market Availability

The BioResolve Protein A Affinity Columns are currently available for order in sizes 2.1 x 20 mm and 3.9 x 5 mm, catering to diverse laboratory needs across the biopharmaceutical research sector.

Conclusion

As Waters Corporation continues to innovate within the biotherapeutics landscape, the introduction of the BioResolve Protein A Affinity Columns stands out as a pivotal advancement. This technology not only emphasizes speed and accuracy in antibody titer measurements but also embodies Waters' commitment to serving the biopharmaceutical community with leading-edge solutions. Looking ahead, this should shape the future of drug development processes, ensuring patients receive critical therapies in a timely manner.

For more details on the technical specifications and applications, visit Waters.com.